Micron's Contract Backlog Strengthens Visibility, But Stock Already Reflects Tight Supply

What happened

Micron's stock has surged about 382% over the past year, prompting questions about whether it is too late to buy, but a new article points out that over a third of future revenue is now under contract, ostensibly providing greater visibility. The master report confirms that Micron has 26 strategic customer agreements covering over 35% of revenue through 2030, with remaining performance obligations of $134 billion and most of 2027 HBM supply already committed at higher prices. However, at $1,029 per share, the stock already discounts sold-out 2027 HBM, an 86% gross margin, and tight DRAM supply into 2028, leaving little room for error against these high expectations. The article's claim that there is still time to buy ignores that the market has been aware of these contracts since the last earnings call and has priced them in, with the stock trading at a P/E of 13.7 times trailing earnings that are likely near peak. Therefore, while the contractual visibility reduces downside risk relative to past cycles, it does not provide a compelling new reason to buy at current levels; better entry points would be below $920 or after further evidence of deepening scarcity.

Implication

The article's argument is not a new catalyst because the contract backlog and customer deposits were already disclosed in Micron's recent filings and are reflected in the stock's 400%+ rally. The key to further upside is whether remaining performance obligations, customer deposits, and letters of credit continue to rise in subsequent quarters, indicating the scarcity is deepening rather than merely persisting. Near-term checkpoints include FQ1 2027 results against guidance of $61.5 billion revenue and 86% gross margin, as well as hyperscaler capex commentary from Microsoft and Meta. Risks are tilted to the downside: any sign of HBM demand softening or competitors accelerating capacity could compress the multiple, and the CEO's recent insider sales add a cautionary note. The prudent strategy is to hold existing positions with a trailing stop and use any decline below $920 as an entry, while avoiding chasing the stock at current prices given the crowded trade and rich valuation.

Thesis delta

No shift. The article highlights the contractual revenue visibility, which is already embedded in the master report's thesis. The stock's valuation remains stretched relative to the base case, and the risk-reward is not compelling at $1,029.